NEW YORK, NY / ACCESSWIRE / June 2, 2016 / There’s quite a lot of talk about small caps not delivering the sort of growth that they used to over the years but the truth is that many investors who hold this belief are simply not paying attention.

Take Galena Biopharma, Inc. (GALE) for instance. The biopharmaceutical company which focuses on developing and commercializing oncology therapeutics, has been having a fantastic last 12 months. The stock has climbed from lows of .59 to trade as high as 2.19 recently. This level of valuation growth comes as the company is making good progress with its NeuVax™ product which recently received fast track designation from the FDA. [1]

Another small cap growth story is Ocean Power Technologies, Inc. (OPTT). OPTT develops and commercializes proprietary systems that generate electricity by harnessing the renewable energy of ocean waves primarily in the United States. Recently it rallied as high as 294%, shaking off doubts after a PB3 PowerBuoy® lease agreement with Mitsui Engineering and Shipbuilding which is valued at approximately $975,000. [2]

How’s that for diversity? Pharmaceuticals and energy generation are as disparate as you get in an investing portfolio but just to prove the underlying spread of small cap growth, here’s another sector that offers up some proof.

Cannabis is one of the biggest growth sectors right now and the small cap growth story which exemplifies this is Blue Line Protection Group, Inc. (BLPG).

BLPG provides armed protection, financial solutions, logistics, and compliance services for businesses engaged in the legal cannabis industry in the United States. It offers asset logistic services comprising armored transportation services; security services, including shipment protection, money escorts, security monitoring, asset vaulting, VIP and dignitary protection, and others; financial services, such as handling transportation and storage of currency; training; and compliance services. [3]

BLPG’s plethora of services is very much a feature of the wide scope of demand that is being generated by cannabis companies. Of course, the most substantial offering from BLPG and any analysis of the current state of the cannabis industry will show why.

>> Could This Undiscovered Cannabis Play Be Ready To Explode? <<

The cannabis industry remains largely cash-based and any given day hundreds of thousands of dollars in cash is being generated in sales. Since most banks refuse to handle the cash generated by cannabis companies, demand for services offered by the likes of BLPG has been growing at an alarming rate. [4]

Demand for these types of services is slated to grow even further due to the increasing number of US states that are considering legalizing cannabis in some form. Currently four states (Colorado, Washington, Oregon, Alaska and Washington, D.C.) have passed laws legalizing the sale of cannabis for recreational use. Additionally, 24 states now allow the sale of cannabis for medical purposes and include markets such as New York, Montana, Maryland and Vermont. The most recent addition was Pennsylvania which passed laws in April 2016. [5]

Nationwide sentiment for legalization is growing faster than lawmakers can establish what to do with the drug. Recent polls show that more than 56% of Americans believe the use of marijuana should be legal and lawmakers are now starting to wake up that wholesale reality. [6]

Blue Line Protection Group, Inc. (BLPG) has been building up its capacity to handle the potential demand for its services. The company announced $500,000 in investment capital from Hypur Ventures, L.P. mid-May 2016. BLPG said in the release that an additional $500,000 may be invested at the discretion of Hypur Ventures. [7]

BLPG has also taken steps to beef up its software compliance platform and recently announced that it has become certified as an integrated software vendor (ISV) of Hypur, Inc.

“As a Hypur ISV, Blue Line expects accelerated growth across its suite of compliance investigations services, with increased penetration into financial institutions seeking integrated client verification assessments,” said the release. [8]

>> See Why This Cannabis Stock Could Be The Biggest Play Of 2016 <<

A major expansion of BLPG’s licensing services division capped a strong period of growth and expansion for the company. In confirming the expansion, BLPG affirmed that, “Its clients require integrated and well-researched security and transportation plans to help ensure maximum return on investment for their business partners. BLPG’s licensing team thoroughly researches each state’s licensing and application requirements, and we work with our clients to develop customized security, transportation and physical surveillance strategies to help increase their odds of winning new licenses.” [9]

Enlightened investors already know what has been illustrated here; the small cap growth story is far from slowing. If anything, it provides the biggest opportunities for the growth investor and the companies outlined offer up the proof and confidence needed for action.

About InvestmentResearchReport.com:

InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else.

Disclosure: DO NOT MAKE ANY TRADING DECISIONS UNTIL YOU HAVE READ OUR FULL DISCLAIMER ON OUR WEBSITE http:/www.investmentresearchreport.com/disclaimer/ . Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Owners and operators of InvestmentResearchReport.com hold no stocks or bonds in any of the stocks mentioned in this release as of 06/02/2016. We have been compensated for this release. Please read the disclaimer at the link above for full compensation details. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Please visit the Investment Research Report website and review the disclaimer link above for complete risks and disclosures.

[1] http://finance.yahoo.com/news/galena-biopharma-receives-fast-track-110500370.html
[2] http://finance.yahoo.com/news/ocean-power-technologies-enters-first-123000805.html
[3] http://www.bluelineprotectiongroup.com
[4] https://www.rt.com/usa/340416-legal-marijuana-businesses-banks/
[5] http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
[6] http://www.cbsnews.com/news/marijuana-use-and-support-for-legal-marijuana-continue-to-climb/
[7] http://finance.yahoo.com/news/blue-line-protection-group-secures-115726340.html
[8] http://finance.yahoo.com/news/blue-line-protection-group-extends-120000613.html
[9] http://finance.yahoo.com/news/blue-line-protection-group-expands-122140196.html

SOURCE: InvestmentResearchReport.com

ReleaseID: 440661

LONDON, UK / ACCESSWIRE / June 2, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Diversified Communication Services industry. Companies recently under review include Gogo, SBA Communications, 8×8, and NeuStar. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

Let us take a brief technical look at how each of the companies mentioned above have fared following their last close and over the last few trading sessions. Additionally, get access to your complimentary research reports on these stocks at:

http://www.activewallst.com/register/

Gogo Inc. (NASDAQ: GOGO)

On Wednesday, shares in communications services provider, Gogo Inc., recorded a trading volume of 2.76 million shares, which was above their three months average volume of 1.29 million shares. The stock ended the session 3.74% lower at $10.82. The Company’s shares have gained 1.12% in the last one month. The stock is trading 2.15% above its 50-day moving average. Moreover, shares of Gogo have a Relative Strength Index (RSI) of 57.67. On May 09th, 2016, research firm Dougherty & Company reiterated its ‘Buy’ rating with an increase of the target price to $17 a share from $16 a share for the Company’s stock.

SBA Communications Corp. (NASDAQ: SBAC)

Florida-based SBA Communications Corp. owns and operates wireless communications tower structures, rooftops, and other structures that support antennas used for wireless communications in the North and South Americas. The Company’s stock closed the day at $98.36, which was a slight correction of 1.05%. A total volume of 1.19 million shares was traded, which was above their three months average volume of 1.11 million shares. The Company’s shares have advanced 2.46% in the previous three months. The stock is trading 2.10% below its 50-day moving average. Additionally, shares of SBA Communications have an RSI of 42.37. On May 03rd, 2016, research firm Stifel reiterated its ‘Buy’ rating with an increase of the target price to $117 a share from $112 a share for the Company’s stock.

8×8 Inc. (NASDAQ: EGHT)

Shares in voice over Internet protocol technology and software as a service communication solutions provider, 8×8 Inc., recorded a trading volume of 896,434 shares, which was higher than their three months average volume of 618,270 shares. The stock ended yesterday’s trading session 3.52% higher at $13.22. The Company’s shares have advanced 12.03% in the past month, 13.57% in the previous three months, and 15.46% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 18.78% and 26.04%, respectively. Furthermore, shares of 8×8 have an RSI of 70.01. On May 20th, 2016, research firm Dougherty & Company reiterated its ‘Buy’ rating with an increase of the target price to $15 a share from $14 a share for the Company’s stock.

NeuStar Inc. (NYSE: NSR)

Sterling, Virginia headquartered tech Company, NeuStar Inc.’s stock finished Wednesday’s session 0.89% higher at $23.76. A total volume of 705,127 shares was traded, which was above their three months average volume of 522,240 shares. The Company’s shares have advanced 1.06% in the last one month. The stock is trading below its 50-day moving average by 1.94%. Additionally, shares of NeuStar have an RSI of 56.22.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440672

NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Deregulated power is slowly becoming the darling of Wall Street investors craving the next big thing. Other growth opportunities are springing up too and companies like Atlantic Power Corporation (AT), one of the key players in the power generation sector is gaining lots of attention. Atlantic Power Corporation owns and operates a fleet of power generation assets in the United States and Canada. [1]

Clean Energy Fuels Corp. (CLNE), which provides natural gas as an alternative fuel for vehicle fleets in the United States and Canada has seen its fortunes rise as the growth opportunities in the energy space take center stage. CLNE recently announced first-quarter net income of $2.8 million; this comes after the company posted a loss in the same quarter in 2015. [2] The news has created fresh interest not just in CLNE, but in other energy-positioned growth opportunities.

Premier Holding Corporation (PRHL) has become a beacon in the deregulated energy space. PRHL acts as an energy holding company focused on acquiring and integrating energy companies as synergistic subsidiaries. It accumulates residential and commercial clients in deregulated markets from all subsidiaries and cross sells energy and energy efficiency products and services.

Premier Holding Corporation (PRHL) has two main growth engines. The first is The Power Company (TPC), an arm that provides competitive energy pricing for customers and also acts as PRHL’s energy consulting service engine. [3]

The other growth engine is E3 – Energy Efficiency Experts. This division was formed by PRHL to provide the best-of-breed energy reduction solutions for its clients. Using a vendor-independent approach, PRHL prescribes the best solution for the unique circumstance of each client and through its ever-growing acquisitions and alliances; E3 continually strives to provide the important management tools enable future client acquisitions. [4]

>> This Undiscovered Deregulated Energy Stock Could Be Poised For A Move Higher <<

Deregulated power has come a long way since the first US states started opening the supply of electricity and natural gas to competition. Deregulation first adopted in 1997 [5] by Rhode Island and since then more and more Energy Service Companies or ESCOs have come on stream, offering consumers greater and greater choice across the board.

The biggest story has surrounded deregulated electricity supply. The market for competitive electricity has seen rapid growth. Estimates peg growth at around $30B [5] per year over the last 10 years and current estimates pegs the market at greater than $180B. Some states have made deregulation their main focus and in Texas for example, the market was more than $35B at the end of 2010.

PRHL has been positioning itself well in this deregulated market. The company recently announced that it has completed the terms of an LOI to purchase a FERC-licensed supplier of deregulated energy from WWCD, an Illinois LLC. [6]

PRHL followed up the LOI news with an announcement that it completed the terms of an MOU with Intellimeter Canada Inc. (ICI), for a Value-Added Reseller (VAR) Agreement.

This agreement, said the release, “authorizes Premier and its subsidiary, Energy Efficiency Experts (E3), to offer this unique technology as part of its overall “Smart Building” technology solution.” [7] PRHL has also joined forces with J. Joseph Inc. to architect the next iteration of its successful internet-based deregulated sales portal. The goal according to PRHL, is to make this technology as much a game changer in this industry as Quotron was for financial data in the age of ticker tape machines. [8]

PRHL has also recorded a 50% increase in sales staff recruitment, [9] a milestone which has prompted the company to announce very ambitious sales projections.

>> This Unique Opportunity Could Give Investors Access To The Upside Of Deregulated Energy <<

A release recently confirmed strong growth numbers for the company going forward. According to the release, PRHL currently generates revenue from commissions on the resale of deregulated power – more than 200,000 residential equivalent contracts have been completed since PRHL made its acquisition three years ago. These contracts have been valued in the market from $60,000,000 to $80,000,000 or more if placed with the supplier, a staggering valuation indeed. [10] PRHL now has the capacity to capture full revenues for the supply of power and has projected that the resale of power should generate over $5,000,000 in revenue for the company’s 2016 fiscal/calendar year. [10]

PRHL expects to generate another $3,000,000 in topline revenue from this supplier as it ramps up. Existing sales infrastructure is projected to increase to over $40 million in 2017 – $95 million in 2018. [10]

The energy supply sectors are poised to deliver high returns and companies such as Premier Holding Corporation (PRHL) are key players that cannot be ignored.

About InvestmentResearchReport.com:

InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else.

Disclosure: DO NOT MAKE ANY TRADING DECISIONS UNTIL YOU HAVE READ OUR FULL DISCLAIMER ON OUR WEBSITE: http://www.investmentresearchreport.com/disclaimer/ . Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Owners and operators of InvestmentResearchReport.com hold no stocks or bonds in any of the stocks mentioned in this release as of 06/02/2016. We have been compensated for this release. Please read the disclaimer at the link above for full compensation details. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Please visit the Investment Research Report website and review the disclaimer link above for complete risks and disclosures.

[1] http://www.atlanticpower.com/
[2] http://finance.yahoo.com/news/clean-energy-fuels-tops-1q-224839354.html
[3] http://prhlcorp.com/about-tpc/
[4] http://prhlcorp.com/
[5] http://www.electricenergyonline.com/show_article.php?article=631
[6] http://finance.yahoo.com/news/mission-accomplished-premier-holding-corporation-110000036.html
[7] http://finance.yahoo.com/news/premier-holding-corporation-signs-value-110000110.html
[8] http://finance.yahoo.com/news/premier-holding-corporation-partners-j-110000003.html
[9] http://finance.yahoo.com/news/premier-holding-corp-subsidiary-power-110000507.html
[10] http://finance.yahoo.com/news/premier-holding-corporation-announces-financial-113000819.html

SOURCE: InvestmentResearchReport.com

ReleaseID: 440660

LONDON, UK / ACCESSWIRE / June 2, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Instruments and Supplies industry. Companies recently under review include Baxter Intl., Skyline Medical, TransEnterix, and DENTSPLY Intl. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

The U.S. Medical Instruments and Supplies market remains to be the largest in the world, and it is expected to grow even more by the end of this year. With increasing competition in the industry, investors are scanning the markets for growth opportunities. Let us see how the current market environment is affecting some of the big names in the industry. Get the full story on these stocks by visiting:

http://www.activewallst.com/register/

ActiveWallSt.com takes a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions and more.

Baxter International Inc. (NYSE: BAX)

Illinois-based renal and hospital products provider, Baxter International Inc.’s stock finished Wednesday’s session 0.39% higher at $43.33 with a total volume of 4.76 million shares traded. The Company’s shares have advanced 9.12% over the previous three months and 13.91% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.39% and 12.71%, respectively. Furthermore, shares of Baxter International have a Relative Strength Index (RSI) of 45.27.

Skyline Medical Inc. (NASDAQ: SKLN)

On Wednesday, shares in Minnesota-based medical device Company, Skyline Medical Inc., ended the session at $0.14, which was a correction of 4.86%. The stock recorded a trading volume of 2.18 million shares. The Company’s shares are trading 28.10% below their 50-day moving average. Moreover, Skyline Medical’s stock has an RSI of 38.94.

TransEnterix Inc. (AMEX: TRXC)

TransEnterix Inc. is a medical device Company that focuses on the development and commercialization of surgical robotic systems. The Company’s stock ended yesterday’s session 2.73% higher at $1.88 with a total volume of 770,803 shares traded. The Company’s shares have advanced 22.08% in the past month. The stock is trading 33.84% below its 200-day moving average. Additionally, shares of TransEnterix have an RSI of 38.89. On May 11th, 2016, research firm Lake Street downgraded the Company’s stock rating from ‘Buy’ to ‘Hold’.

DENTSPLY International Inc. (NASDAQ: XRAY)

At the close on Wednesday, shares in York, Pennsylvania-based dental consumable products provider, DENTSPLY International Inc., recorded a trading volume of 1.39 million shares. The stock finished 0.51% higher at $62.48. The Company’s shares have advanced 3.70% in the last one month, 3.92% in the previous three months, and 2.81% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.69% and 6.94%, respectively. Furthermore, shares of DENTSPLY International have an RSI of 57.41. On May 13th, 2016, research firm Barrington Research reiterated its ‘Outperform’ rating with an increase of the target price to $68 a share from $62 a share for the Company’s stock.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.   

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440670

LONDON, UK / ACCESSWIRE / June 2, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Asset Management industry. Companies recently under review include Och-Ziff Capital Management, Legg Mason, Eaton Vance, and SEI Investments. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

Let us take a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions. You can also register for our free membership and access the complimentary research report service for these stocks at:

http://www.activewallst.com/register/

Och-Ziff Capital Management Group LLC (NYSE: OZM)

On Wednesday, shares in New York-based hedge fund sponsor, Och-Ziff Capital Management Group LLC, recorded a trading volume of 439,637 shares, and ended the day 1.49% higher at $4.09. The stock has gained 2.25% in the last one month. The Company’s shares are trading above their 50-day moving average by 4.41%. Furthermore, Och-Ziff Capital Management Group’s stock has a Relative Strength Index (RSI) of 57.97. On May 31st, 2016, research firm RBC Capital Markets reiterated its ‘Outperform’ rating with a decrease of the target price to $7 a share from $8 a share for the Company’s stock.

Legg Mason Inc. (NYSE: LM)

Maryland-based asset management holding Company, Legg Mason Inc.’s stock finished yesterday’s session at $34.22, which was a slight correction of 0.81%. A total volume of 1.31 million shares was traded. The Company’s shares have gained 7.27% in the last one month and 11.85% over the previous three months. The stock is trading above its 50-day moving average by 3.54%. Furthermore, shares of Legg Mason have an RSI of 61.61. On May 02nd, 2016, research firm RBC Capital Markets reiterated its ‘Sector Perform’ rating with an increase of the target price to $41 a share from $35 a share for the Company’s stock.

Eaton Vance Corp. (NYSE: EV)

At the closing bell on Wednesday, shares in Eaton Vance Corp., which through its subsidiaries, engages in the creation, marketing, and management of investment funds in the U.S., climbed 0.14%, ending the day at $36.41. The stock recorded a trading volume of 1.26 million shares, which was higher than its three months average volume of 812,260 shares. The Company’s shares have advanced 4.99% in the last one month, 19.68% in the previous three months, and 14.17% since the start of this year. The stock is trading 5.88% above its 50-day moving average and 10.69% above its 200-day moving average. Moreover, shares of Eaton Vance have an RSI of 63.44.

SEI Investments Co. (NASDAQ: SEIC)

Oaks, Pennsylvania headquartered investment manager, SEI Investments Co.’s stock ended the day at $51.26, which was a slight correction of 0.35%. A total volume of 630,912 shares was traded. The Company’s shares have gained 4.76% in the last month, 29.05% over the previous three months, and 8.12% on an YTD basis. The stock is trading 9.76% above its 50-day moving average and 8.30% above its 200-day moving average. Additionally, shares of SEI Investments have an RSI of 70.06.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440673

LONDON, UK / ACCESSWIRE / June 2, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Entertainment Diversified industry. Companies recently under review include Comcast, Twenty-First Century Fox, Walt Disney, and Time Warner. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

The Entertainment Diversified industry for a number of investors has always been interesting to watch, as it presents numerous growth opportunities. Let us see what are the market and economic factors affecting some of the big names in the industry. Gain access to these stocks’ research report by clicking on the following link:

http://www.activewallst.com/register/

ActiveWallSt.com takes a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions and more.

Comcast Corp. (NASDAQ: CMCSA)

Pennsylvania-based media and technology Company, Comcast Corp.’s stock finished Wednesday’s trading session 0.68% higher at $63.73 with a total volume of 7.69 million shares traded. The Company’s shares have advanced 4.08% in the past month, 7.82% in the previous three months, and 13.95% on an YTD basis. The stock is trading 3.89% above its 50-day moving average and 8.51% above its 200-day moving average. Additionally, shares of Comcast have a Relative Strength Index (RSI) of 66.04.

Twenty-First Century Fox Inc. (NASDAQ: FOXA)

On Wednesday, shares in New York headquartered diversified media and entertainment operator, Twenty-First Century Fox Inc., recorded a trading volume of 11.70 million shares, which was above their three months average volume of 8.99 million shares. The stock ended the session 1.63% higher at $29.35. The Company’s shares have advanced 6.96% in the previous three months and 8.65% since the start of this year. The stock is trading 0.65% above its 50-day moving average and 4.87% above its 200-day moving average. Moreover, shares of Twenty-First Century Fox have an RSI of 55.55. On May 23rd, 2016, research firm Credit Suisse reiterated its ‘Outperform’ rating with an increase of the target price to $40 a share from $37 a share for the Company’s stock.

The Walt Disney Co. (NYSE: DIS)

Shares in California-based broadcast and cable television networks operator, The Walt Disney Co., closed the day at $98.52, which was a slight correction of 0.71%. The stock recorded a trading volume of 7.23 million shares. The Company’s shares have gained 1.57% over the previous three months. The stock is trading 2.07% below its 50-day moving average. Additionally, shares of Walt Disney have an RSI of 39.81. On May 11th, 2016, research firm Topeka Capital Markets reiterated its ‘Buy’ rating with a decrease of the target price to $129 a share from $130 a share for the Company’s stock.

Time Warner Inc. (NYSE: TWX)

At the close on Wednesday, shares in Time Warner Inc., which Time Warner Inc. operates as a media and entertainment Company in the U.S. and globally, finished at $76.41, gaining 0.99%. The stock recorded a trading volume of 4.82 million shares, which was higher than its three months average volume of 4.58 million shares. The Company’s shares have advanced 2.01% in the last one month, 15.09% in the previous three months, and 19.52% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.93% and 9.31%, respectively. On May 02nd, 2016, research firm Pacific Crest downgraded the Company’s stock rating from ‘Outweight’ to ‘Sector Weight’.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440669

LONDON, UK / ACCESSWIRE / June 2, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Independent Oil and Gas industry. Companies recently under review include Warren Resources, Matador Resources, Kosmos Energy, and Bellatrix Exploration. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

As stated by the most recent data from the U.S. Energy Information Administration, U.S. crude oil production in March 2016 averaged 9.127 million b/d, down from 9.133 million b/d in February 2016 and 9.648 million b/d in March 2015. The overall drop in the U.S. crude output was driven by a more than 10% decline year-over-year in Texas. Let us see how this is affecting some of the big names in the industry. Know more about these companies by accessing their full report at:

http://www.activewallst.com/register/

ActiveWallSt.com looks at the performance of the companies mentioned above over the last few trading sessions.

Warren Resources Inc. (NASDAQ: WRES)

Colorado-based independent energy Company, Warren Resources Inc.’s stock finished Wednesday’s session at $0.13, which was a correction of 2.91%. A total volume of 642,633 shares was traded. Over the previous three months, the Company’s shares have surged 30.00%. The stock is trading below its 50-day moving average by 9.43%. Moreover, shares of Warren Resources have a Relative Strength Index (RSI) of 50.04.

Matador Resources Co. (NYSE: MTDR)

Shares in Texas headquartered Matador Resources Co., which engages in the exploration, development, production, and acquisition of oil and natural gas resources in the U.S., ended yesterday’s session 0.62% higher at $22.86 with a total volume of 969,122 shares traded. The stock has gained 4.67% in the past month, 27.28% in the previous three months, and 15.63% on an YTD basis. The Company’s shares are trading 9.57% above their 50-day moving average and 9.71% above their 200-day moving average. Moreover, Matador Resources’ stock has an RSI of 61.13. On May 05th, 2016, research firm Wunderlich reiterated its ‘Buy’ rating with an increase of the target price to $28 a share from $25 a share for the Company’s stock.

Kosmos Energy Ltd (NYSE: KOS)

On Wednesday, Bermuda-based oil and gas exploration and producer, Kosmos Energy Ltd’s stock saw a correction of 2.44%, to close the day at $5.60. A total volume of 1.63 million shares was traded. The Company’s shares have advanced 10.02% in the previous three months and 7.69% since the start of this year. The stock is trading 1.78% below its 50-day moving average. Additionally, shares of Kosmos Energy have an RSI of 54.02. On May 11th, 2016, research firm Raymond James upgraded the stock’s ratings from ‘Outperform’ to ‘Strong Buy’.

Bellatrix Exploration Ltd (NYSE: BXE)

Shares in Calgary, Canada based Bellatrix Exploration Ltd, which operates mainly in the provinces of Alberta, British Columbia, and Saskatchewan, ended the day at $0.93, which was a correction of 3.11%. A total volume of 1.57 million shares was traded, which was above their three months average volume of 1.35 million shares. The stock is trading below its 50-day moving average by 8.71%. Furthermore, shares of Bellatrix Exploration have an RSI of 41.02.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440671

TULSA, OK / ACCESSWIRE / June 2, 2016 / AppSwarm, Inc. (OTCPink: SWRM), a cutting edge application incubation and development firm continues its investment in new executive talent with the hiring of John Rabbitt as Chief Financial Officer (CFO).

As CFO at AppSwarm, Mr. Rabbitt will be responsible for ensuring that the finance organization can enable the company to drive growth, capitalizing on the growing worldwide demand for software application solutions, financial governance and risk management across the spectrum of financial operations.

“John brings terrific skills to our finance and accounting team from his experience at several growing companies where he was instrumental in providing the finance vision, strategy and leadership to help the organizations get to the next level,” Ron Brewer, CEO, AppSwarm, said. “With John at the finance helm, I’m assured we’ll be well positioned to meet our growth goals moving forward.”

John’s extensive and diverse background in business evolved through consistent promotion and growth within fortune 500 firms including The Pillsbury Company and PepsiCo, in addition to the CPA firm of Ernst and Ernst. This experience is enhanced by a twenty year career with one of America’s most successful Entrepreneurs (Forbes 102nd wealthiest U.S.A. person in 2008) where John was directly involved with numerous acquisitions and served in executive capacities for several multinational subsidiaries. John played a key role in assisting the growth of MEI Corporation from $20 million in annual revenue to $850 million in annual revenue in nine years, at which time it was acquired by PepsiCo.

Mr. Rabbitt has served in CEO/COO and CFO positions for firms ranging from $5,000,000 to $300,000,000 in annual revenue. He also served as a member of PepsiCo’s MidWest Advisory Board, and as a Director and Secretary/Treasurer of their largest canning division.

Mr. Rabbitt’s education includes a BA in Accounting and Business from Drake University, graduate work at Xavier University in Cincinnati, and PepsiCo’s Management Institute.

About
AppSwarm, Inc.

Established in 2011, AppSwarm™ is an application incubation firm dedicated to acquiring applications for all forms of devices. We have resources most small firms or young entrepreneurs and application developers usually do not have to market applications the most effective way possible. We have agreements in place with major application stores so we can fast track projects. We offer complete end-to-end services for mobile application development across all major platforms including Apple iPhone, RIM’s BlackBerry, Google’s Android, as well as Microsoft’s Windows Mobile. With our extensive experience in the mobile space, we cannot only give applications a technical hand, but can be a strategic partner in leveraging this dynamic mobile world towards increased business efficiency and effectiveness. For more information visit www.app-swarm.com.

DISCLOSURES: “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

800-706-7656
info@app-swarm.com

SOURCE: AppSwarm, Inc.

ReleaseID: 440654

NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).

The note is available here: TPIV Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“We note that TPIV and the Mayo Clinic announced positive Phase 1 clinical data from the Folate Receptor Alpha trial in triple negative breast and ovarian cancer in 2H15, which demonstrated the experimental therapy was safe, well-tolerated and provided a robust immune response in 19 out of 20 patients. With three Phase 2 trials / studies commencing in 2016, we expect continued updates from the company over the next 12-24 months, including an updated on additional IND applications to the FDA, which could serve as possible catalysts for the company or the company’s potential partnership discussions,” stated Ajay Tandon, Chief Executive Officer of SeeThruEquity.

Additional highlights of the note are as follows:

Large market opportunity for TPIV’s immunotherapy platform

The company’s lead candidate, TPIV-200, is a multi-epitope peptide vaccine that targets Folate Receptor Alpha, which is overexpressed in multiple cancers including over 90% of ovarian cancer cells. TPIV’s platform immunotherapy technology is initially being explored as a potential therapy for ovarian, triple-negative breast, and Her2neu cancers, though the company believes it has potential to treat a number of cancels as a standalone treatment of in combination with other approved products. Although the company is clinical-stage, we note that the potential market for its products is vast, if it receives FDA approval. According to IMS Health, the global market for cancer drugs has eclipsed $100 billion per year in sales, and the cancer immunotherapy market is one of the fastest-growing segments of this market – estimated to to reach $41 billion in major markets by 2020E, according to researchandmarkets.com.

New Phase 2 clinical study with AstraZeneca to begin at Memorial Sloan Kettering Cancer Center in 2Q16

We have been impressed by the quality of collaborative partners announced by TPIV as it commences Phase 2 clinical studies for its lead candidate, TPIV-200. Most recently, TPIV announced a new Phase 2 clinical study of TPIV-200 for ovarian cancer that will be jointly funded with major pharmaceutical corporate AstraZeneca PLC (NYSE: AZN). TPIV and AstraZeneca will supply drug in a Phase 2 clinical study of its cancer vaccine, TPIV 200, in combination with AstraZeneca’s durvalumab (MEDI4736), in a single arm, study at Memorial Sloan Kettering Cancer Center, commencing in 2Q16. This development follows an announcement in 2H15 that the company’s longstanding research partner the Mayo Clinic had received a $13.3mn grant from the Department of Defense to fund a 280-patient Phase 2 clinical trial of TPIV-200 for breast cancer. In addition, TapImmune will conduct a company-sponsored Phase 2 clinical study of TPIV-200 in Triple Negative Breast Cancer and file a new IND application with the FDA for HER2neu breast cancer in early 2017E. Accordingly, we expect to see significant clinical progress from TPIV during the next 24 months.

Price target of $2.25 for TPIV

TPIV continues to make substantial clinical progress, and we are impressed by the quality of partners that the company has been able to attract in its Phase 2 studies. We are updating our price target at this time for TPIV to reflect the current share count and warrants outstanding, which is higher than our original valuation. If achieved, the price target of $2.25 represents upside potential of 268.9% from the recent price of $0.61.

Please review important disclosures on our website at www.seethruequity.com.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at http://www.tapimmune.com for details.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 440678

NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus – invisible, silent; an autoimmune disease where the body’s defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood…the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) poses a potential solution with its drug hCDR1 designed to battle systemic lupus erythematosus (SLE), accounting for 70% of lupus cases and intended to treat not just lupus’ manifestations, but the disease itself. If approved, sales would commence into a market projected to $4 billion by 2022, only six years away.

Its drug works by correcting what lupus does: improper regulation of immunology-aids cytokines, B-cells and T-cells. hCDR1 is a short chain of amino acids that stimulates regulatory T-cells, reducing inflammation and bringing the immune system into needed balance. XTL acquired rights to hCDR1 two years ago from Yeda Research and Development Co. in Israel, after Teva Pharmaceuticals (NYSE: TEVA) gave licensing rights back to Yeda after Teva’s expansive, 340-patient Phase II PRELUDE study on hCDR1 was discontinued due to lack of achieving a primary endpoint of lowered lupus disease activity.

So why would XTL find interest in the drug? Simply (and luckily) because FDA changed its measurement of endpoint results. Teva’s study used the traditional SLE Disease Activity Index that rates all organs with one score. FDA found this not sufficient to evaluate lupus drugs and adopted the British Isles Lupus Activity Group score, more accurate by rating each organ independently. XTL saw that PRELUDE’s results, measured under BILAG, were better with a certain dosage showing meaningful impact. Hence, a new trial under a different rule.

Working efficiently and effectively with the FDA, XTL completed its Phase II trial design for hCDR1 set to start after a New Drug Application is filed, with hopes to begin enrollment this year. BILAG measurement of organ improvement, the trial’s primary endpoint, must occur in at least one organ, according to agency feedback. A global study, double-blind and placebo controlled lasting for 26 weeks, both safety and efficacy will be evaluated.

Dose escalation will also be determined, even though PRELUDE found 0.5 mg to be optimal. When speaking to CEO Josh Levine as to why alternate doses are used, he replied there might be better data at a lower dose. Also veering from PRELUDE’s trial design, steroids will be limited.

Only a handful of FDA-approved drugs for lupus are marketed. Anti-inflammatory, immunosuppressant corticosteroid Prednisone is one, typically used for milder cases of SLE, first introduced over 60 years ago. Its biggest drawback is, naturally, a compromised immune response where exposure to infection becomes more dangerous. Patients are at higher risk for osteoporosis and Kaposi’s sarcoma.

More severe SLE is treated with anti-cancer compound methotrexate although again, the ability to fight infection is lessened and chemotherapy-like side effects are common. Lupus is not cancer, yet doctors often opt for anti-cancer remedies when other methods are lacking and nothing better exists. Another chemotherapy, Cytoxan usually reserved for blood cancers or rheumatoid arthritis, is an immunosuppressant to relieve lupus sufferers from kidney inflammation. Side effects include skin rash, decline in immunity-necessary white blood cells, risk of shingles, and infertility. Prolonged use at high doses has been linked to bladder cancer

Not much better, an immunosuppressant known as CellCept synthesized years ago by Roche Holding (OTC: RHHBY), is claimed in medical circles to act as an effective first-line defense for lupus patients with inflamed kidneys who need to reduce treatment with steroids. Side effects can be detrimental to quality of life, such as shakiness, abdominal pain and peripheral limb swelling. Birth defects have been observed.

Most recent is GlaxoSmithKline’s (NYSE: GSK) monoclonal antibody Benlysta, with 2015 sales of USD340 million, up 25% from the prior year despite a host of adverse effects similar to anti-cancer drugs: nausea, vomiting and low white blood cell count. Mental health issues like depression and thoughts of suicide have also been observed. Regardless, growth in Benlysta sales should be positively impacted by the current rise in lupus interest.

Recent data shows lupus can lead to dementia, pegged to steroid use. Over 1,000 lupus patients followed for seven years were twice as likely to sink into cognitive disability. Lupus is now viewed an even greater public health risk, one that could lead to lifelong disability.

XTL’s drug has shown time and again its good effect on lupus by suppressing wayward immune system components to prevent inflammation. By using hCDR1, cytokines that would otherwise contribute to inflammation are rendered ineffective and helpful cytokines take over. This is a truly novel approach to fight SLE. Other studies, of the 40 extant, proved a drop in production of bad cytokines (certain interferons and interleukins) and an increase in production of cells that cause a beneficial effect in this often silent disease. Many of these studies have been done in the Weismann Institute in Israel, renowned for innovative medical technologies.

Offering a stream of benefits to emerging companies, the European Medicines
Agency’s Small or Medium Sized Business Enterprise status was granted to XTL, who will then enjoy lower fees for phased clinical trials (including post-marketing studies, if required), lots of free advice, and grant eligibility.

Lupus, recognized as a ‘cruel mystery’ by advocate groups, grabbed public attention in May as the first annual Lupus Awareness Month. Almost two-thirds of the world’s population has no clue what lupus is, or whether it’s a disease, and almost 50% considered it contagious. A groundswell of help is emerging: petitions aimed at the World Health Organization, dedicated to global health issues, urge inclusion of lupus in its chronic disease programs and better education and support of this misunderstood and often lethal disease.

Following designation as lupus awareness month, the World Lupus Federation was launched, creating a global string of patient groups in 16 countries aimed to enhance education of lupus as a worldwide public health problem.

XTL is serious about its commitment to lupus: last January, management was invited and accepted a position on Lupus Foundation of America’s corporate advisory council, where its role will be to bring forward and support better lupus treatment. In March, top lupus specialist Daphna Paran, MD, joined as Medical Director with the belief that hCDR1 has good potential, a strong testimony for someone of her background.

XTL had approximately $3.8 million in the bank as of December 31, 2015. Like most clinical-stage biotechs embarking on advanced studies, research and development spending doubled from 2014, to $578,000 while cost-containment in general and administrative moderated 17%, to $1.4 million. Net loss was higher at $4.3 million, but reflected an intangible asset impairment charge from abandoning other clinical projects for hCDR1 in favor of devoting time to SLE.

I view XTL as a company with a lower risk profile than other firms at a similar stage of life. Teva’s work with hCDR1, particularly safety data, is recognized by FDA officials. A new endpoint measure has been established. Still, standard risks are present: inability to replicate Teva’s low side effect results; regulatory glitches; slower-than-expected enrollment; and the need for more cash. More specifically, shares are very thinly traded.

This company is one where investment should be considered. Lupus is a large market and growing. Attention for education and call for better drugs is mounting. XTL’s clinical advisors have vast experience with lupus and its management team holds impressive, relevant pedigrees. Former studies yielded good results, and the upcoming Phase II will mimic its design. Most rewarding, hCDR1 offers rheumatologists a shift from current, suboptimal treatments for debilitating and sometimes fatal lupus, to a promising and life-changing solution.

About Small Cap Forecasting,
Inc.

Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and bio-pharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense. Ms. di Stefano received a Master’s of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.

Media contact:

Jackie Rodriguez

646-430-5783

SOURCE: Small Cap Forecasting, Inc.

ReleaseID: 440657